Wacharapluesadee, Supaporn
Tan, Chee Wah http://orcid.org/0000-0001-9837-1413
Maneeorn, Patarapol
Duengkae, Prateep
Zhu, Feng http://orcid.org/0000-0002-8131-1219
Joyjinda, Yutthana
Kaewpom, Thongchai
Chia, Wan Ni
Ampoot, Weenassarin
Lim, Beng Lee
Worachotsueptrakun, Kanthita
Chen, Vivian Chih-Wei http://orcid.org/0000-0001-8757-0644
Sirichan, Nutthinee
Ruchisrisarod, Chanida
Rodpan, Apaporn
Noradechanon, Kirana
Phaichana, Thanawadee
Jantarat, Niran
Thongnumchaima, Boonchu
Tu, Changchun http://orcid.org/0000-0002-8134-7502
Crameri, Gary
Stokes, Martha M.
Hemachudha, Thiravat
Wang, Lin-Fa http://orcid.org/0000-0003-2752-0535
Funding for this research was provided by:
MOH | National Medical Research Council (COVID19RF-003, STPRG-FY19-001)
National Research Foundation Singapore (NRF2016NRF-NSFC002-013)
Article History
Received: 14 December 2020
Accepted: 18 January 2021
First Online: 9 February 2021
Change Date: 27 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-21768-2
Competing interests
: L.-F.W., C.W.T., and W.N.C. are inventors of a patent application for the SARS-CoV-2 sVNT, which has been commercialized by GenScript Biotech under the tradename cPass<sup>TM</sup>. Other authors declare no competing interests.